High Macrophage Inhibitory Cytokine-1 Levels and Colorectal Cancer Risk

Get Permission

Chronic inflammation is implicated in the development of colorectal cancer, and the plasma inflammatory biomarker macrophage inhibitory cytokine-1 (MIC-1, GDF15) may have a direct role in tumorigenesis.

As reported in Journal of the National Cancer Institute, Mehta and colleagues found that subjects in the highest (5th) quintile of plasma MIC-1 as measured by enzyme-linked immunosorbent assay had significantly increased risk of colorectal cancer (relative risk [RR] = 1.93, P = .004 for trend) compared with the lowest quintile on multivariate analysis in a nested case-control study.

Further, for patients in the four highest MIC-1 quintiles, regular use vs nonuse of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with significantly reduced risk of prostaglandin-endoperoxide synthase 2 (PTGS2)/cyclooxygenase-2 (COX-2)–positive colorectal cancer (RR = 0.60, 95% confidence interval [CI] = 0.41– 0.88) but not PTGS2-negative colorectal cancer (RR = 1.21, 95% CI = 0.71–2.07).

Aspirin and NSAID use was not associated with a significantly altered risk of PTGS2-positive colorectal cancer (RR = 0.57, 95% CI = 0.21–1.54) or PTGS2-negative colorectal cancer (RR = 1.41, 95% CI = 0.47–4.23) in patients in the lowest MIC-1 quintile.

The investigators concluded, “Our results support an association between higher levels of circulating MIC-1 (GDF15) and [colorectal cancer]. Aspirin/NSAID use appeared to lower risk of PTGS2-positive cancers, particularly among individuals with high levels of circulating MIC-1.” ■

Mehta RS, et al: J Natl Cancer Inst 106(4):dju016, 2014.

Lab Notes is compiled and written for The ASCO Post by Matthew Stenger.





By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.